CHF Drug Trial Standards Debated By Natrecor Advisory Committee
Executive Summary
If sponsors of acute congestive heart failure drug studies need to limit the patient population, they should focus on non-catheterized patients, FDA Cardio-Renal Drug Products Division Director Raymond Lipicky, MD, suggested during a May 25 advisory committee meeting.
You may also be interested in...
Scios Natrecor Pharmacoeconomic Study To Address Length Of Stay Concerns
Scios Natrecor pharmacoeconomic study will address advisory committee concern about a one-day longer hospital stay for Natrecor than for nitroglycerin, CEO Richard Brewer told analysts following the committee meeting May 25.
Pfizer Cardura Potential Labeling Changes Should Await More Data - Cmte.
Any potential changes to Pfizer's antihypertensive therapy Cardura (doxazosin) labeling should await additional data from NIH's ALLHAT study, FDA's Cardiovascular & Renal Drugs Advisory Committee said May 24.
Scios Natrecor Physician Education Should Address Hypotension Risk
Scios' Natrecor physician education program should highlight the potential for symptomatic hypotension with the decompensated congestive heart failure treatment, FDA's Cardiovascular & Renal Drugs Advisory Committee said May 25.